核酸扩增检测在有症状细菌性阴道病和外阴阴道念珠菌病女性中检测性传播感染的临床效用:传统与分子诊断的比较
该研究比较了在1,039例有症状阴道炎女性中,采用传统方法或分子诊断(NAAT)诊断细菌性阴道病(BV)和外阴阴道念珠菌病(VVC)后,STI-NAAT检测阴道毛滴虫、沙眼衣原体、淋病奈瑟菌和生殖支原体的诊断效用。结果显示,BV-NAAT阳性者STI检出率显著高于HCP诊断BV者(95.5% vs 87.0%,P=0.0408),且BV-NAAT阳性与任何STI感染的相对风险显著升高(RR 1.85,95%CI 1.43-2.39,P<0.0001)。结论提示联合分子检测可提高诊断 yield。
要点
- BV-NAAT阳性者STI检出率显著高于HCP诊断BV者(95.5% vs 87.0%,P=0.0408)。
- BV-NAAT阳性与任何STI感染的相对风险显著升高(RR 1.85,95%CI 1.43-2.39,P<0.0001)。
- VVC-NAAT阳性者STI阳性率高于HCP诊断VVC者(93.2% vs 30.5%),但差异无显著性。
核心结论
- 联合分子检测STI和BV/VVC相比传统实验室方法或HCP评估可提高诊断 yield。
研究设计与样本
- 对1,039例有症状阴道炎女性进行STI-NAAT(TV、CT、NG、MG)比较分析,其中823例经HCP临床评估、传统实验室方法或BV/VVC-NAAT诊断BV和/或VVC。
主要发现
- 在508例传统实验室诊断BV的女性中,BV-NAAT阳性者STI检出147/154(95.5%),显著高于HCP诊断BV者的134/154(87.0%)(P=0.0408)。
- 在培养阳性VVC女性中,VVC-NAAT阳性者STI-NAAT阳性率为55/59(93.2%),HCP诊断VVC者为18/59(30.5%),差异无显著性。
- BV-NAAT阳性与任何STI感染的相对风险显著升高(RR 1.85;95%CI 1.43-2.39,P<0.0001),VVC中STI-NAAT阳性感染的相对风险未显著升高。
- BV/VVC-NAAT阳性诊断的女性STI-NAAT阳性率高于传统临床经验诊断BV/VVC的女性。
临床怎么用
- 对有症状阴道炎女性采用联合分子检测(STI和BV/VVC NAAT)可提高STI病例发现,优于传统实验室方法或临床评估后的STI-NAAT检测。
- 联合分子检测策略可改善风险分层,支持指南一致的STI检测,并简化临床和实验室工作流程(单一标本、单一方法)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Numerous studies describe increased rates of sexually transmitted infections (STIs) in women with symptomatic vaginitis from various causes. We present a comparative analysis of the diagnostic utility of STI nucleic acid amplification testing (NAAT) for Trichomonas vaginalis (TV), Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) in 1,039 women with symptomatic vaginitis, including 823 women diagnosed with bacterial vaginosis (BV) and/or vulvovaginal candidiasis (VVC) by in-office health care provider (HCP) clinical assessment, conventional laboratory methods (Nugent Score/Amsel Criteria/culture), or BV- and VVC-NAAT methods. Among 508 women with a conventional laboratory BV diagnosis, significantly more STIs were detected in women with a positive BV-NAAT result (147/154, 95.5%) compared to women with HCP diagnosis of BV (134/154, 87.0%; P = 0.0408). For women with a culture-positive VVC diagnosis, a higher STI-NAAT positivity rate correlated with a positive VVC-NAAT result (55/59, 93.2%) compared to HCP VVC diagnosis (18/59, 30.5%), although this difference was not significant. A positive vs negative BV-NAAT result had a significantly higher relative risk for any STI infection (RR: 1.85; 95% confidence interval [CI] 1.43-2.39, P < 0.0001), while relative risks for STI-NAAT positive infections were not elevated significantly in VVC. Finally, STI NAAT positivity rates were higher in women with positive BV/VVC NAAT vaginitis diagnoses compared to women diagnosed with BV/VVC by conventional clinician empirical diagnosis. These results indicate combined molecular testing for STIs, and BV/VVC has improved diagnostic yield compared to conventional laboratory methods or traditional HCP assessment for these disorders.IMPORTANCEAn all-molecular (nucleic acid amplification test [NAAT]-based) approach to vaginitis and sexually transmitted infection (STI) testing of vaginal swabs from women with symptomatic vaginitis provides optimal STI case finding comparable to using STI NAATs after traditional lab-based methods for vaginitis diagnosis and better than using STI NAATs following a clinician's assessment for vaginitis diagnosis. This study demonstrates that a combined molecular testing strategy to identify the causes of vaginitis and STIs can improve risk stratification, support guideline-aligned STI testing, help clinicians provide the most appropriate and comprehensive care, and streamline clinical and laboratory workflows using a single specimen and single test method (NAAT).
引用
- Getman D, Seña AC, Nenninger A, et al. Clinical utility of nucleic acid amplification testing for detection of sexually transmitted infections in women with symptomatic bacterial vaginosis and vulvovaginal candidiasis identified by conventional versus molecular diagnoses. J Clin Microbiol. 2026. PMID: 42626953. doi:10.1128/jcm.00117-26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。